Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc. achieved a new 52-week high of USD 75.01 on October 15, 2025, reflecting a 131.18% increase over the past year. The company, with a market cap of USD 2,402 million, has shown positive sales growth and rising promoter confidence, enhancing its industry standing.

Tarsus Pharmaceuticals, Inc. has achieved a new 52-week high, reflecting its strong performance in the pharmaceuticals and biotechnology sector. With a market capitalization of USD 2,402 million, the company has shown significant growth, positive quarterly results, and increasing promoter confidence, highlighting its resilience and commitment to future prospects.

Tarsus Pharmaceuticals, Inc. achieved a new 52-week high on October 8, 2025, reflecting its strong performance in the pharmaceuticals and biotechnology sector. With a market cap of USD 2,402 million, the company has shown resilience despite losses, and promoter confidence is increasing as their stake rises.

Tarsus Pharmaceuticals, Inc. achieved a new 52-week high of USD 69.49 on October 7, 2025, reflecting strong performance in the pharmaceuticals sector. With a market cap of USD 2,402 million and significant net sales, the company has seen increased promoter confidence and impressive one-year growth metrics.

Tarsus Pharmaceuticals, Inc. achieved a new 52-week high of USD 68.00 on October 6, 2025, reflecting a 108.87% increase over the past year. The company, with a market cap of USD 2,402 million, has shown improving financial results and rising promoter confidence, indicating potential growth in the pharmaceuticals sector.

Tarsus Pharmaceuticals, Inc. has recently revised its evaluation amid strong market dynamics, with its stock price rising significantly. Over the past year, the company has achieved a remarkable return, outperforming the S&P 500. Technical indicators show a predominantly bullish sentiment, reflecting Tarsus's growth potential in the pharmaceuticals sector.

Tarsus Pharmaceuticals, Inc. has shown notable market activity, with a significant stock increase today and impressive gains over the past week and year. The company, operating in the Pharmaceuticals & Biotechnology sector, has reported positive quarterly results and rising promoter confidence, reflecting its strong performance in the market.

Tarsus Pharmaceuticals, Inc. achieved a new 52-week high of USD 65.97 on October 3, 2025, reflecting a 101.02% increase over the past year. The company, with a market cap of USD 2,402 million, has shown positive sales growth and rising promoter confidence despite ongoing losses.

Tarsus Pharmaceuticals, Inc. has recently undergone a revision in its score, reflecting its strong market performance and operational resilience. The company has achieved impressive returns over the past year and three years, significantly outperforming the S&P 500. Positive quarterly results and increased promoter stake further underscore its robust market position.

Tarsus Pharmaceuticals, Inc. achieved a new 52-week high of USD 59.77, reflecting its strong performance in the pharmaceuticals sector with an 83.31% increase over the past year. The company has shown improvements in operational efficiency and rising promoter confidence, with stakeholders increasing their holdings.

Tarsus Pharmaceuticals, Inc. has shown impressive stock performance, gaining 7.29% on September 30, 2025, and achieving significant growth over the past year and three years. The company reported record quarterly net sales of USD 102.66 million and increased stakeholder confidence, highlighting its resilience in the pharmaceuticals sector.

Tarsus Pharmaceuticals, Inc. has recently revised its evaluation amid current market dynamics. The stock has shown significant performance over the past year, with a notable return that exceeds the S&P 500. Technical indicators suggest a generally positive sentiment among traders, reflecting the company's resilience in the Pharmaceuticals & Biotechnology sector.